In Gilead, two former employees alleged that Gilead, a pharmaceutical company, made false statements in the course of obtaining FDA approval for several HIV drugs, for which the company later sought reimbursement through federal programs such as Medicare and Medicaid. Among other things, relators alleged that Gilead used ingredients produced by an unregistered source, Synthetics China. Relators also asserted that had the FDA been aware of these regulatory violations, it would have denied approval for these drugs, and Gilead would not have been eligible for payment through any of the federal reimbursement programs.